Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Provide information about a student’s past immunization for meningitis, or confirm that the student will not be immunized. If student is a minor, you can also use this form to provide consent for ...

Other than the adjuvant melanoma study, other late-stage trials in BMS' current pipeline listing that mention the LAG-3 inhibitor include RELATIVITY-1093 in first-line non-small cell lung cancer ...

Health and immunization records submitted to or generated by Student Health Services are held on file for 7 years from the date of submission. Consent is required from students 18 years old and over, ...

Patients with high-risk pathological features either after neoadjuvant chemotherapy or who are cisplatin-ineligible undergo centralized ctDNA testing post-surgery. ctDNA-positive patients are ...